Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: A Sonoclot in vitro study

References

• Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:7498–508.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010;126:175–82.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–27.
   PubMed Web of Science ®Google Scholar
• Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493–502.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985–97.
   PubMed Web of Science ®Google Scholar
• Fries D, Giurea A, Gütl M, Halbmayer WM, Kozek- Langenecker S, Pachucki A, Roithinger F, Steinlechner B, Thaler H, Weltermann A. Management of dabigatran- induced bleeding: expert statement. Wien Klin Wochenschr 2013;125:721–9
   PubMed Web of Science ®Google Scholar
• Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87:141–5.
   PubMed Web of Science ®Google Scholar
• Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008;106:1366–75.
   PubMed Web of Science ®Google Scholar
• Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 2007;105:933–9.
   PubMed Web of Science ®Google Scholar
• Cheng SS, Nordenholz K, Matero D, Pearlman N, McCarter M, Gajdos C. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med 2012;38:624–48.
   Web of Science ®Google Scholar
• Wang JQ, Shi XB, Yang JG, Hu DY. In vitro anticoagulation monitoring of low-molecular-weight heparin. Chin Med J 2009;122:1199–202.
   PubMed Web of Science ®Google Scholar
• Nilsson CU, Engström M. Monitoring fondaparinux with the Sonoclot. Blood Coagul Fibrinolysis 2007;18:619–22.
   PubMed Web of Science ®Google Scholar
• Aggarwal V, Kapoor PM, Choudhury M, Kiran U, Chowdhury U. Utility of Sonoclot analysis and tranexamic acid in tetralogy of Fallot patients undergoing intracardiac repair. Ann Card Anaesth 2012;15:26–31.
   PubMedGoogle Scholar
• Saxena P, Bihari C, Rastogi A, Agarwal S, Anand L, Sarin SK. Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies. Adv Hematol 2013;2013:237351.
   PubMedGoogle Scholar
• Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69–75.
   PubMed Web of Science ®Google Scholar
• Ganter MT, Schmuck S, Hamiel CR, Wischmeyer PE, Heule D, Zollinger A, Hofer CK. Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. J Cardiothorac Vasc Anesth 2008;22:675–80.
   PubMed Web of Science ®Google Scholar
• Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003;1:551–8.
   PubMed Web of Science ®Google Scholar
• Viuff D, Andersen S, Sørensen BB, Lethagen S. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients. Thromb Res 2010;126:144–9.
   PubMed Web of Science ®Google Scholar
• Young G, Zhang R, Miller R, Yassin D, Nugent DJ. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia 2010; 16:518–24.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47–59.
   PubMed Web of Science ®Google Scholar
• He S, Wallèn H, Bark N, Blombäck M. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban. J Thromb Thrombolysis 2012;35:131–9.
   Web of Science ®Google Scholar
• Aron JL, Gosselin R, Moll S, Arkin CF, Mantha S. Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran- associated intracranial hemorrhage. J Thromb Thrombolysis 2014;37:76–9.
   PubMed Web of Science ®Google Scholar
• Engström M, Rundgren M, Schött U. An evaluation of monitoring possibilities of atrgatroban using rotational thromboelastometry and activated partial thromboplastin time. Acta Anaesthesiol Scand 2010;54:86–91.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436–50.
   PubMed Web of Science ®Google Scholar
• Khoo TL, Weatherburn C, Kershaw G, Reddel CJ, Curnow J, Dunkley S. The use of FEIBA(®) in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol 2012;35:222–4.
   PubMed Web of Science ®Google Scholar
• Dumkow LE, Voss JR, Peters M, Jennings DL. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.Am J Health Syst Pharm 2012;69:1646–50.
   PubMed Web of Science ®Google Scholar
• Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother 2012;10:160–3.
   PubMed Web of Science ®Google Scholar
• Schulman S, Ritchie B, Goy JK, Nahirniak S, Almutawa M, Ghanny S. Activated prothrombin complex concentrate for dabigatran-associated bleeding. Br J Haematol 2014; 164:308–10
   PubMed Web of Science ®Google Scholar
• Faust AC, Peterson EJ. Management of dabigatran- associated intracerebral and intraventricular hemorrhage: a case report. J Emerg Med 2014;46:525–9.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172–4.
   PubMed Web of Science ®Google Scholar
• Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61:487–9.
   PubMed Web of Science ®Google Scholar
• Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46:21.
   PubMedGoogle Scholar
• Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011;7:281–7.
   PubMedGoogle Scholar
• Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012;69: 1473–84.
   PubMed Web of Science ®Google Scholar
• Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989;56:603–9.
   PubMed Web of Science ®Google Scholar
• Takeyama M, Sakurai Y, Shima M, Matsumoto T, Nogami K, Tanaka I, Takeda T, Giddings JC, Yoshioka A. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. Blood Coagul Fibrinolysis 2007;18:1–7.
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573–9.
   PubMed Web of Science ®Google Scholar
• Sørensen B, Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.Thromb Haemost 2006;96:446–53.
   PubMed Web of Science ®Google Scholar
• Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108;217–42.
   PubMed Web of Science ®Google Scholar
• Davis PK, Musunuru H, Walsh M, Mitra R, Ploplis V, Castellino FJ. The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine. Thromb Haemost 2012;108:586–8.
   PubMed Web of Science ®Google Scholar
• Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2013;19:111(5).
   Google Scholar
• Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554–62.
   PubMed Web of Science ®Google Scholar
• Grottke O, van Ryn J, Spronk HM, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014;18:R27.
   PubMed Web of Science ®Google Scholar
• Ekbäck G, Carlsson O, Schött U. Sonoclot coagulation analysis: a study of test variability. J Cardiothorac Vasc Anesth 1999;13:393–7.
   PubMed Web of Science ®Google Scholar
• Forestier F1, Bélisle S, Contant C, Harel F, Janvier G, Hardy JF. Reproducibility and interchangeability of the Thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery. Can J Anaesth 2001;48:902–10.
   PubMed Web of Science ®Google Scholar
• Horlocker TT, Schroeder DR. Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations. Mayo Clin Proc 1997; 72:214–9.
   PubMed Web of Science ®Google Scholar